Synaptogenix (TAOX) Competitors $6.71 +0.19 (+2.91%) As of 12:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock TAOX vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Aravive Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Synaptogenix (NASDAQ:TAOX) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment. Which has better valuation and earnings, ATNFW or TAOX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ASynaptogenixN/AN/A-$12.77M-$10.08-0.67 Do insiders and institutionals believe in ATNFW or TAOX? 10.3% of Synaptogenix shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ATNFW or TAOX more profitable? 180 Life Sciences' return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Synaptogenix N/A -115.28%-58.31% Does the media favor ATNFW or TAOX? In the previous week, 180 Life Sciences had 1 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for 180 Life Sciences and 1 mentions for Synaptogenix. 180 Life Sciences' average media sentiment score of 0.94 beat Synaptogenix's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 180 Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summary180 Life Sciences beats Synaptogenix on 4 of the 6 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for TAOX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAOX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$9.33M$777.32M$2.25B$9.53BDividend YieldN/A4.84%2.56%4.05%P/E Ratio-0.671.3922.1620.00Price / SalesN/A24.8375.0785.63Price / CashN/A19.5626.5028.40Price / Book1.556.8241.545.73Net Income-$12.77M-$4.22M-$62.28M$259.24M7 Day PerformanceN/A-0.36%-0.13%-0.23%1 Month PerformanceN/A4.65%2.23%10.53%1 Year PerformanceN/A10.39%9.78%15.04% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAOXSynaptogenixN/A$6.71+2.9%N/AN/A$9.33MN/A-0.674News CoverageAnalyst UpgradeATNFW180 Life SciencesN/A$0.01+16.3%N/A+4.0%$0.00N/A0.007Gap DownHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.14-15.7%N/AN/A$0.00$106.21K0.0040Gap DownALVOWAlvotechN/A$2.66+36.4%N/A-25.1%$0.00$585.60M0.004Gap UpARAVAraviveN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05-0.6%N/AN/A$0.00N/A0.0015High Trading VolumeBFRIWBiofronteraN/A$0.20+105.9%N/AN/A$0.00$38.00M0.0070BTMDWbioteN/A$0.01-14.7%N/A-97.6%$0.00$199.38M0.00N/AGap UpBCTXWBriaCell TherapeuticsN/A$0.04-29.8%N/A-77.7%$0.00N/A0.008News CoverageGap Down Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Aravive Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TAOX) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TAOX Stock Alerts